AAOMS Annual Meeting

The FDA has approved the expansion of the age indication for FluLaval Quadrivalent.

The FDA has approved the expansion of the age indication for FluLaval Quadrivalent.

The FDA approved Xultophy 100/3.6 for the reduction of A1c in adults with type 2 diabetes inadequately controlled by basal insulin or liraglutide alone.

The FDA approved Xultophy 100/3.6 for the reduction of A1c in adults with type 2 diabetes inadequately controlled by basal insulin or liraglutide alone.

The FDA approved Xultophy 100/3.6 for the reduction of A1c in adults with type 2 diabetes inadequately controlled by basal insulin or liraglutide alone.

The FDA has approved Soliqua 100/33 for the treatment of adults with type 2 diabetes that has been inadequately controlled with basal insulin or lixisenatide.

The FDA has approved Soliqua 100/33 for the treatment of adults with type 2 diabetes that has been inadequately controlled with basal insulin or lixisenatide.

The FDA has approved Soliqua 100/33 for the treatment of adults with type 2 diabetes that has been inadequately controlled with basal insulin or lixisenatide.

The FDA makes its website accessible for the widest possible audience to get up to date information and alerts.

The FDA makes its website accessible for the widest possible audience to get up to date information and alerts.